High in vivo production of a model monoclonal antibody on adenoviral gene transfer

Human Gene Therapy

Volumn 13, Issue 12, 2002, Pages 1483-1493

  Noël, Danièle ^a,b   Pelegrin, Mireia ^b   Kramer, Susanne ^b   Jacquet, Chantal ^b   Skander, Nadia ^b   Piechaczyk, Marc ^b  

^a INSERM   (France)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; THYROGLOBULIN ANTIBODY;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATOCYTES; HUMANS; MICE; MICE, INBRED C57BL; MUSCLE FIBERS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0036382827     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340260185111     Document Type: Article

References (31)

1. ANTOINE, B., LEVRAT, F., VALLET, V., BERBAR, T., CARTIER, N., DUBOIS, N., BRIAND, P., and KAHN, A. (1992). Gene expression in hepatocyte-like lines established by targeted carcinogenesis in transgenic mice. Exp. Cell Res. 200, 175-185.
2. DANTHINNE, X., and IMPERIALE, M.J. (2000). Production of first generation adenovirus vectors: A review. Gene Ther. 7, 1707-1714.
3. DAUTZENBERG, H., SCHULDT, U., GRASNICK, G., KARLE, P., MULLER, P., LOHR, M., PELEGRIN, M., PIECHACZYK, M., ROMBS, K.V., GUNZBURG, W.H., SALMONS, B., and SALLER, R.M. (1999). Development of cellulose sulfate-based polyelectrolyte complex microcapsules for medical applications. Ann. N.Y. Acad. Sci. 875, 46-63.
4. DEL RIO, M., PAU, B., BASTIDE, M., and BOUANANI, M. (1995). Idiotypic restriction of murine monoclonal antibodies to a defined antigenic region of human thyroglobulin. Immunol. Invest. 24, 655-667.
5. v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6, 1520-1535.
6. FROMES, Y., SALMON, A., WANG, X., COLLIN, H., ROUCHE, A., HAGEGE, A., SCHWARTZ, K., and FISZMAN, M.Y. (1999). Gene delivery to the myocardium by intrapericardial injection. Gene Ther. 6, 683-688.
7. GLENNIE, M.J., and JOHNSON, P.W. (2000). Clinical trials of antibody therapy. Immunol. Today 21, 403-410.
8. GURA, T. (2002). Therapeutic antibodies: Magic bullets hit the target. Nature 417, 584-586.
9. ISAACS, J.D. (1990). The antiglobulin response to therapeutic antibodies. Semin. Immunol. 2, 449-456.
10. KIMURA, E., MAEDA, Y., ARIMA, T., NISHIDA, Y., YAMASHITA, S., HARA, A., UYAMA, E., MITA, S., and UCHINO, M. (2001). Efficient repetitive gene delivery to skeletal muscle using recombinant adenovirus vector containing the coxsackievirus and adenovirus receptor cDNA. Gene Ther. 8, 20-27.
11. KUUS-REICHEL, K., GRAUER, L.S., KARAVODIN, L.M., KNOTT, C., KRUSEMEIER, M., and KAY, N.E. (1994). Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1, 365-372.
12. MAIONE, D., WIZNEROWICZ, M., DELMASTRO, P., CORTESE, R., CILIBERTO, G., LA MONICA, N., and SAVINO, R. (2000). Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther. 11, 859-868.
13. MALONEY, D.G., GRILLO, L.A., WHITE, C.A., BODKIN, D., SCHILDER, R.J., NEIDHART, J.A., JANAKIRAMAN, N., FOON, K.A., LILES, T.M., DALLAIRE, B.K., WEY, K., ROYSTON, I., DAVIS, T., and LEVY, R. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195.
14. MCLAUGHLIN, P., GRILLO-LOPEZ, A.J., LINK, B.K., LEVY, R., CZUCZMAN, M.S., WILLIAMS, M.E., HEYMAN, M.R., BENCEBRUCKLER, I., WHITE, C.A., CABANILLAS, F., JAIN, V., HO, A.D., LISTER, J., WEY, K., SHEN, D., and DALLAIRE, B.K. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833.
15. MONTARRAS, D., CHELLY, J., BOBER, E., ARNOLD, H., OTT, M.O., GROS, F., and PINSET, C. (1991). Developmental patterns in the expression of Myf5, MyoD, myogenin, and MRF4 during myogenesis. New Biol. 3, 592-600.
16. NOËL, D., PELEGRIN, M., MARIN, M., BIARD, P.M., OURLIN, J.C., MANI, J.C., and PIECHACZYK, M. (1997). In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum. Gene Ther. 8, 1219-1229.
17. NOËL, D., PELEGRIN, M., BROCKLY, F., LUND, A.H., and PIECHACZYK, M. (2000). Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts. J. Invest. Dermatol. 115, 740-745.
18. NOËL, D., DAZARD, J.E., PELEGRIN, M., JACQUET, C., and PIECHACZYK, M. (2002). Skin as a potential organ for ectopic antibody production. J. Invest. Dermatol. 118, 288-294.
19. PARKS, R.J. (2000). Improvements in adenoviral vector technology: Overcoming barriers for gene therapy. Clin. Genet. 58, 1-11.
20. PELEGRIN, M., and PIECHACZYK, M. (2001). Application of recombinant antibodies in gene transfer and gene therapy. In Therapeutic Antibody Technology. T. Kieber-Emmons and Z. Steplewski, eds. (Marcel Dekker, New York) (in press).
21. PELEGRIN, M., MARIN, M., NOËL, D., and PIECHACZYK, M. (1998a). Genetically engineered antibodies in gene transfer and gene therapy. Hum. Gene Ther. 9, 2165-2175.
22. PELEGRIN, M., MARIN, M., NOËL, D., DEL RIO M., SALLER, R., STANGE, J., MITZNER, S., GUNZBURG, W.H., and PIECHACZYK, M. (1998b). Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther. 5, 828-834.
23. PELEGRIN, M., NOËL, D., MARIN, M., BACHRACH, E., SALLER, R., SALMONS, B., and PIECHACZYK, M. (1998c). In vivo production of therapeutic antibodies by engineered cells for immunotherapy of cancer and viral diseases. Gene Ther. Mol. Biol. 3, 1-9.
24. PELEGRIN, M., MARIN, M., OATES, A., NOËL, D., SALLER, R., SALMONS, B., and PIECHACZYK, M. (2000). Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum. Gene Ther. 11, 1407-1415.
25. PIECHACZYK, M., CHARDES, T., COT, M.-C., PAU, B., and BASTIDE, J.-M. (1985). Production and characterization of monoclonal antibodies against human thyroglobulin. Hybridoma 4, 361-367.
26. SOYKAN, I., ERTAN, C., and OZDEN, A. (2000). Severe anaphylactic reaction to Infliximab: Report of a case. Am. J. Gastroenterol. 95, 2395-2396.
27. SVENSSON, E.C., BLACK, H.B., DUGGER, D.L., TRIPATHY, S.K., GOLDWASSER, E., HAO, Z., CHU, L., and LEIDEN, J.M. (1997). Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum. Gene Ther. 8, 1797-1806.
28. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2, 545-550.
29. VIEIRA, P., and RAJEWSKY, K. (1988). The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 18, 313-316.
30. WANG, I.I., and HUANG, I.I. (2000). Adenovirus technology for gene manipulation and functional studies. Drug Discov. Today 5, 10-16.
31. 99mTc-labeled adenovirus knob (serotype 5). Gene Ther. 5, 798-808.